切换至 "中华医学电子期刊资源库"

中华妇幼临床医学杂志(电子版) ›› 2011, Vol. 07 ›› Issue (05) : 476 -480. doi: 10.3877/cma.j.issn.1673-5250.2011.05.020

综述

1-脱氨基-8-D-精氨酸血管加压素治疗血友病的研究进展
白松婷, 盛光耀   
  1. 450052 郑州,郑州大学第一附属医院儿科
  • 出版日期:2011-10-01

Research Progress of 1-Deamino-8-D-Arginine-Vasopressin in the Treatment of Patients With Hemophilia

Song-ting BAI, Guang-yao SHENG   

  1. Department of Pediatrics, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
  • Published:2011-10-01
  • Supported by:
    * Project No. 200801004, supported by the Science and Technical Project of the Ministry of Health
引用本文:

白松婷, 盛光耀. 1-脱氨基-8-D-精氨酸血管加压素治疗血友病的研究进展[J]. 中华妇幼临床医学杂志(电子版), 2011, 07(05): 476-480.

Song-ting BAI, Guang-yao SHENG. Research Progress of 1-Deamino-8-D-Arginine-Vasopressin in the Treatment of Patients With Hemophilia[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2011, 07(05): 476-480.

1-脱氨基-8-D-精氨酸血管加压素(DDAVP)是人工合成的血管加压素类药物,可提高健康人群及血友病(hemophilia)患者血浆因子Ⅷ(F Ⅷ)、von Willebrand因子(vWF)及组织型纤溶酶原激活物(t-PA)水平。在国外,DDAVP成功用于防治轻型血友病A(HA)、1型血管性血友病导致的出血事件,已有30多年历史。越来越多研究证实,DDAVP对女性HA携带者、已有抑制物产生的HA及获得性HA, 甚至对血友病B(HB),也有一定治疗作用。DDAVP使用安全、价格低廉,尤其可降低因使用血液制品导致的人体免疫缺陷病毒(HIV)、肝炎病毒等的传播及因反复使用外源性FⅧ导致的FⅧ抑制性抗体产生的危险。因此,建议对新诊断为血友病的患者,也应进行DDAVP应答测试,以评估患者在将来防治出血性事件时使用该药的可能性和方案。

1-deamino-8-D-arginine-vasopressin (DDAVP) is a synthetic compound of the antidiuretic hormone vasopressin, which can increase plasma concentration of factor Ⅷ (FⅧ), von Willebrand factor (vWF), and tissue plasminogen activator (t-PA) in normal subjects and patients with hemophilia A(HA). It has been using for the treatment or prevention of bleeding episodes caused by mild HA and type 1 von Willebrand disease (vWD) over the past 30 years on aboard. More and more studies have demonstrated the clinical efficacy of DDAVP for carriers of female HA, patients of HA with inhibitors and acquired HA, even for patients with haemophilia B(HB). DDAVP is safe, cheap and carries no risk of transmitting of blood-borne viral infections particularly during the human immunodeficiency virus (HIV) and hepatitis virus, and developing inhibitor antibodies upon repeated treatments with FⅧ concentrates. Thus, in every patient with newly diagnosed as hemophilia, a test infusion/injection of DDAVP should be carried out to assess the future usefulness of the compound.

1 Castaman G. Desmopressin for the treatment of haemophilia [J]. Haemophilia, 2008, 14(Suppl 1): 15-20.
2 Castaman G, Mancuso ME, Giacomelli SH, et al. Molecular and phenotypic determinants of response to desmopressin in adult patients with mild hemophilia A[J]. J Thromb Hemost, 2009,7:1824-1831.
3 Kaufmann JE, Oksche A, Wollllheim CB, et al. Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP[J]. J Clin Invest, 2000, 106:107-116.
4 Federici AB. The use of desmopressin in von Willebrand disease:The experience of the first 30 years(1977-2007)[J]. Haemophilia, 2008, 14(Suppl 1):5-14.
5 Franchini M, Zaffanello M, Lippi G. The use of desmopressin in mild hemophilia A[J]. Blood Coagul Fibrinolysis, 2010, 21(7):615-619.
6 Lethagen S, Harris AS, Nilsson IM. Intranasal desmopressin (DDAVP) by spray in mild hemophilia A and von Willebrand's disease type I[J]. Blut, 1990, 60: 187-191.
7 Rodeghiero F, Castaman G, DiBona E, et al. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand' s disease and hemophilia A [ J]. Blood, 1989, 74: 1997-2000.
8 Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP) [J]. Br J Haematol, 1992, 82: 87-93.
9 Ozgonenel B, Rajpurkar M, Lusher JM. How do you treat bleeding disorders with desmopressin [J]? Postgrad Med J, 2007, 83(977):159-163.
10 Franchini M, Mannucci PM. Co-morbidities and quality of life in elderly persons with hemophilia [J]. Br J Hematol, 2010, 148:522-533.
11 Franchini M, Favaloro EJ, Lippi G. Mild hemophilia A [ J]. J Thromb Hemost, 2010, 8(3): 421-432.
12 Franchini M, Zaffanello M, Lippi G. The use of desmopressin in mild hemophilia A[J]. Blood Coagul Fibrinolysis, 2010, 21(7):615-619.
13 Lethagen S. Desmopressin in mild hemophilia A: Indications, limitations, efficacy, and safety [J]. Semin Thromb Hemost, 2003, 29: 101-106.
14 Castaman G, Mancuso ME, Giacomelli SH, et al. Molecular and phenotypic determinants of response to desmopressin in adult patients with mild hemophilia A[J]. J Thromb Haemost, 2009, 7: 1824-1831.
15 Riccardi F, Rivolta GF, Franchini M, et al. Characterization of a novel mutation in the F8 promoter region associated with mild hemophilia A and resistance to DDAVP therapy[J]. J Thromb Haemost, 2009, 7: 1234-1235.
16 De la Fuente B, Kasper CK, Rickles FR, et al. Response of patients with mild and moderate hemophilia A and von Willebrand's disease to treatment with desmopressin [J]. Ann Intern Med, 1985, 103: 6-14.
17 Leissinger C, Becton D, Cornell C, et al. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A[J]. Haemophilia, 2001, 7: 258-266.
18 Mannucci PM. Use of desmopressin (DDAVP) during early pregnancy in factor Ⅷ-deficient women [J]. Blood, 2005, 105:3382.
19 Nolan B, White B, Smith J, O'Reilly C, et al. Desmopressin: Therapeutic limitations in children and adults with inherited coagulation disorders[J]. Br J Haematol, 2000, 109: 865-869.
20 Revel-Vilk S, Blanchette V, Sparling C, et al. DDAVP challenge tests in boys with mild/moderate haemophilia A [J]. Br J Haematol, 2002, 117: 947-951.
21 Sharathkumar A, Lillicrap D, Blanchette VS, et al. Intensive exposure to factor Ⅷ is a risk factor for inhibitor development in mild hemophilia A[J]. J Thromb Haemost, 2003, 1: 1228-1236.
22 Shima M. Diagnosis and treatment of acquired hemophilia [J]. Rinsho Ketsueki, 2010, 51: 1531-1538.
23 Ehl S, Severin T, Sutor HS. DDAVP (desmopressin; 1-deaminocys-8-d-arginine-vasopressin) treatment in children with haemophilia B[J]. Br J Haematol, 2000, 111: 1260-1262.
24 Federici AB. The use of desmopressin in von Willebrand disease:The experience of the first 30 years(1977-2007)[J]. Haemophilia, 2008, 14(Suppl 1): 5-14.
25 Castaman G, Lethagen S, Federici AB, et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (vWD): Results from the European Study MCMDM-1 vWD[J]. Blood, 2008, 111(7): 3531-3539.
26 Castaman G, Eikenboom JCJ, Rodeghiero F, et al. A novel candidate mutation (Arg 611→His) in type 1 "platelet discordant" von Willebrand's disease with desmopressin-induced thrombocytopenia [J]. Br J Haematol, 1995, 89: 656-659.
27 Federici AB, Rand JH, Bucciarelli P, et al. Acquired von Willebrand syndrome: Data from an international registry [J]. Thromb Haemost, 2000, 84: 345-349.
[1] 唐蜜, 蔡江晖, 罗尔丹, 郭文玫, 熊丽玲, 林永红, 邢莎莎, 杨霄. 多肽疫苗治疗乳腺癌的临床研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(05): 309-313.
[2] 张蓝心, 高天琦, 徐岭植, 李曼. 激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌的治疗进展[J]. 中华乳腺病杂志(电子版), 2022, 16(06): 365-369.
[3] 田艳, 孙明霞, 吴世凯. 乳腺癌化疗剂量强度的认识与发展[J]. 中华乳腺病杂志(电子版), 2022, 16(02): 106-109.
[4] 刘战涛, 宋艳秋. 乳腺癌的靶向治疗[J]. 中华乳腺病杂志(电子版), 2021, 15(06): 329-336.
[5] 杨继鑫, 李南林. 细胞周期蛋白依赖激酶4和6抑制剂研究进展[J]. 中华乳腺病杂志(电子版), 2021, 15(05): 315-319.
[6] 邓玉燕, 庞永慧, 莫钦国, 谭虹虹, 茅传兰, 陈菲菲. 新辅助化疗对乳腺癌改良根治术后并发症及凝血功能的影响[J]. 中华乳腺病杂志(电子版), 2021, 15(05): 283-287.
[7] 邵雅斐, 吴红丽, 姚艳丽. 微创灌洗配合口服中药治疗浆细胞性乳腺炎的临床研究[J]. 中华乳腺病杂志(电子版), 2021, 15(04): 218-222.
[8] 孙长鲛, 许平平, 谢兰兰, 李慧敏, 杨凯, 蔡谞, 陈连旭. 合并血友病患者全膝关节置换术的手术挑战[J]. 中华关节外科杂志(电子版), 2022, 16(06): 771-775.
[9] 尚宏喜, 贺敬龙, 郝敏, 丁强, 孙炜, 刘安庆, 谢伟. 全膝关节置换术在重度血友病性关节炎的疗效分析[J]. 中华关节外科杂志(电子版), 2021, 15(06): 753-757.
[10] 胡青, 余海燕. 胎儿宫内治疗及风险评估[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(01): 23-30.
[11] 叶长缨, 谢静, 丁桂聪. 乳牙龋病的过渡性治疗研究进展[J]. 中华口腔医学研究杂志(电子版), 2023, 17(05): 365-370.
[12] 张成仁, 杨熊飞, 杜斌斌, 柳利利, 李晶晶, 朱成章, 吴德望, 吕耀春. 转移灶不可切除的无症状结直肠癌是否行原发灶肿瘤切除术的Meta分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(03): 305-310.
[13] 高英杰, 王阳, 王丽红, 毕文静, 刘卫民. VWF基因突变导致混合痔术后大出血一例报告并文献复习[J]. 中华临床医师杂志(电子版), 2023, 17(04): 496-498.
[14] 赵江红, 严东琴, 黄美婷, 余艳萍. 早期妊娠合并甲状旁腺功能亢进一例并文献复习[J]. 中华产科急救电子杂志, 2021, 10(04): 230-235.
[15] 罗纯苑, 刘杭鑫, 李玥, 麦艳梅, 石凌波. 一例产后获得性血友病A报告及总结分析[J]. 中华临床实验室管理电子杂志, 2023, 11(02): 114-117,123.
阅读次数
全文


摘要